Waking,broke MA50, Cash/share $1.3 PPS. Completed Enrollment in Pivotal Efficacy Trial for M207 for Acute Migraine early month.Early 2017 catalysts.
52wk Range
0.45 - 3.20
As of November 3, 2016, the registrant had a total of 16,815,997 (about 10m cap right now)
Cash and cash equivalents $ 19,178,000
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.